Abstract
Cardiac dyssynchrony refers to disparity in cardiac wall motion, a serious consequence of myocardial infarction associated with poor outcome. Infarct-induced scar is refractory to device-based cardiac resynchronization therapy, which relies on viable tissue. Leveraging the prospect of structural and functional regeneration, reparative resynchronization has emerged as a potentially achievable strategy. In proof-of-concept studies, stem-cell therapy eliminates contractile deficit originating from infarcted regions and secures long-term synchronization with tissue repair. Limited clinical experience suggests benefit of cell interventions in acute and chronic ischemic heart disease as adjuvant to standard of care. A regenerative resynchronization option for dyssynchronous heart failure thus merits validation.
Original language | English (US) |
---|---|
Pages (from-to) | 1055-1060 |
Number of pages | 6 |
Journal | Expert Opinion on Biological Therapy |
Volume | 14 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2014 |
Keywords
- Biologics
- Cardiac resynchronization therapy
- Clinical trial
- Dyssynchrony
- Heart failure
- Myocardial infarction
- Regenerative medicine
- Stem cells
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry